VERACYTE, INC. VCYT revenue by segment, product and geography
In its fiscal year ending 2025-12-31, VERACYTE, INC. reported revenue across 1 business segments; the largest, Reportable Segment, was $517M, 100.0% of the filed sum (+16.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$517M100.0%+16.0% yoy
Members sum to the consolidated $517M for this period.
- Testing$493Mshare n/a+17.7% yoy
- Product$14.3Mshare n/a+5.0% yoy
- Biopharmaceutical And Other$9.66Mshare n/a-26.5% yoy
- Biopharmaceutical And Other Biopharmaceutical Revenue$6.54Mshare n/a-8.6% yoy
- Testing Other$6.2Mshare n/a-47.5% yoy
- Biopharmaceutical And Other Contract Manufacturing And Testing$3.13Mshare n/a-47.9% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$497M96.0%+17.3% yoy
- Outside the United States$20.5M4.0%-7.6% yoy
Members sum to the consolidated $517M for this period.
- Reportable Segment$150M100.0%+15.5% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.